Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s “Breakthrough” Evolves: What’s Next For The Popular Program?

This article was originally published in RPM Report

Executive Summary

FDA’s second wave of Breakthrough Therapies will look markedly different from the initial flurry of approvals. After an early focus on oncology, FDA is reviewing a more diverse set of applications in the antiviral, vaccines and cardiovascular arenas. And there will be more “breaks” during development as sponsors start to request designations based on earlier data. What will Breakthrough look like in the third year of the program?

Advertisement

Related Content

Breakthrough Nears 50 Approvals: Process Improving, But “Gray Areas” Persist
Breakthrough Nears 50 Approvals: Process Improving, But “Gray Areas” Persist
FDA Outlines “Expedited” Review For Breakthrough Therapies; “Hyper-Fast” Reviews, Beyond Oncology
Zykadia Expedited Timeline Challenged By Late-Breaking GMP Concern
Sovaldi NDA Review Marred By Manufacturing Compliance Issues
Cancer Therapies: The Breakthrough Era
FDA’s Call for Quality: Revamped GMP Initiative Stresses Cost Savings
FDA’s “Breakthrough” Exceeds Expectations; Will It Break The Bank?
Genentech’s Cancer Product Line Expands, As Do Its Post-Market Manufacturing Obligations
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel